Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight

This article was originally published in PharmAsia News

Executive Summary

The Indian health minister Anbumani Ramadoss urged Novartis earlier this month to end its legal bid to win patent protection for its oncologic Gleevec, or he said the government may override existing patents for vitally necessary drugs by issuing licenses that allow Indian generic manufacturers to produce cheaper versions in the interest of public health

You may also be interested in...



Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System

Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.

Intellectual Property In India: Novartis Sees Patent Protections To Be In Patients’ Best Interests (Part 3 of 3)

Novartis’ Gleevec patent battle in India has caught the attention of at least one U.S. lawmaker. Meanwhile, the outcome could impact Indian pharmas.

Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)

Novartis argues India’s interpretation of the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights agreement is too strict and focuses too much on efficacy to the exclusion of bioavailability.

UsernamePublicRestriction

Register

LL1130096

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel